{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T04:54:50Z","timestamp":1781585690055,"version":"3.54.5"},"reference-count":11,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP19fk0108150"],"award-info":[{"award-number":["JP19fk0108150"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP20fk0108150"],"award-info":[{"award-number":["JP20fk0108150"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.jiac.2022.10.008","type":"journal-article","created":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T21:25:17Z","timestamp":1666733117000},"page":"150-156","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Favipiravir for symptomatic COVID-19: A nationwide observational cohort study"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9620-2525","authenticated-orcid":false,"given":"Yohei","family":"Doi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuma","family":"Ishihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumi","family":"Banno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2891-5424","authenticated-orcid":false,"given":"Masahiko","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jiac.2022.10.008_bib1","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res"},{"issue":"1","key":"10.1016\/j.jiac.2022.10.008_bib2","doi-asserted-by":"crossref","first-page":"4682","DOI":"10.1038\/s41467-020-18463-z","article-title":"Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis","volume":"11","author":"Shannon","year":"2020","journal-title":"Nat Commun"},{"issue":"7","key":"10.1016\/j.jiac.2022.10.008_bib3","doi-asserted-by":"crossref","first-page":"e00819","DOI":"10.1128\/AAC.00819-20","article-title":"Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs","volume":"64","author":"Jeon","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"43","key":"10.1016\/j.jiac.2022.10.008_bib4","doi-asserted-by":"crossref","first-page":"26955","DOI":"10.1073\/pnas.2014441117","article-title":"Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity","volume":"117","author":"Kaptein","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.jiac.2022.10.008_bib5","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1038\/s41467-021-21992-w","article-title":"Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model","volume":"12","author":"Driouich","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jiac.2022.10.008_bib6","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ijid.2022.04.035","article-title":"The efficacy and adverse effects of favipiravir on patients with COVID-19: a systematic review and meta-analysis of published clinical trials and observational studies","volume":"120","author":"Hung","year":"2022","journal-title":"Int J Infect Dis"},{"issue":"4","key":"10.1016\/j.jiac.2022.10.008_bib7","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.cmi.2021.12.026","article-title":"Efficacy of favipiravir in adults with mild COVID-19: a randomized, double-blind, multicentre, placebo-controlled clinical trial","volume":"28","author":"Bosaeed","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jiac.2022.10.008_bib8","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciac312","article-title":"Favipiravir for treatment of outpatients with asymptomatic or uncomplicated COVID-19: a double-blind randomized, placebo-controlled, phase 2 trial","author":"Holubar","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2022.10.008_bib9","article-title":"Favipiravir in patients with early mild-to-moderate COVID-19: a randomized controlled trial","author":"Golan","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.jiac.2022.10.008_bib10","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1620\/tjem.251.87","article-title":"Uric acid elevation by favipiravir, an antiviral drug","volume":"251","author":"Mishima","year":"2020","journal-title":"Tohoku J Exp Med"},{"issue":"12","key":"10.1016\/j.jiac.2022.10.008_bib11","doi-asserted-by":"crossref","first-page":"e01897","DOI":"10.1128\/AAC.01897-20","article-title":"A prospective, randomized, open-label trial of early versus late favipiravir therapy in hospitalized patients with COVID-19","volume":"64","author":"Doi","year":"2020","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X22002914?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X22002914?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T19:05:26Z","timestamp":1761159926000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X22002914"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":11,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S1341321X22002914"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2022.10.008","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Favipiravir for symptomatic COVID-19: A nationwide observational cohort study","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2022.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}